Overview

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc.
Grifols Therapeutics LLC
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin